New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT05687136

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This early-phase trial is testing two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find the safest dose and understand side effects. About 66 adults with specific genetic changes in their tumors will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Phone: •••-•••-••••

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    RECRUITING

    New York, New York, 10016, United States

    Contact

    Contact Email: •••••@•••••

  • Massachusetts General Hospital Cancer Center

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact Phone: •••-•••-••••

  • NYU Langone Hospital - Long Island

    RECRUITING

    Mineola, New York, 11501, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Cancer Institute Developmental Therapeutics Clinic

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact

    Contact Phone: •••-•••-••••

  • National Institutes of Health Clinical Center

    ACTIVE_NOT_RECRUITING

    Bethesda, Maryland, 20892, United States

Conditions

Explore the condition pages connected to this study.